regulatory
confidence high
sentiment positive
materiality 0.75
FDA clears Intellia's IND for NTLA-2001 Phase 3 trial in ATTR cardiomyopathy
Intellia Therapeutics, Inc.
- First-ever in vivo CRISPR candidate to enter late-stage clinical development (Phase 3).
- Global Phase 3 study expected to initiate by year-end 2023.
- NTLA-2001 is a single-dose, systemically administered CRISPR therapy targeting TTR gene.
- Intellia collaborates with Regeneron on development and commercialization.